Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome

The medication enhances insulin secretion when blood glucose levels are elevated, suppresses glucagon release (a hormone that raises blood sugar), slows gastric emptying, and reduces appetite
Some of the more common peptide therapies There are many different types of peptide therapies on the market today
Faurschou A, Knop FK, Thyssen JP, et al
This high-dose formula helps to enhance detoxification, boost immune function, and promote radiant skin by reducing oxidative stress and supporting cellular health